Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.

Zuleger CL, Kang C, Ranheim EA, Kurzman ID, Macklin MD, Newton MA, Wolchok JD, Vail DM, Eriksson E, Albertini MR.

Vet Med Sci. 2017 May 22;3(3):134-145. doi: 10.1002/vms3.65. eCollection 2017 Aug.

2.

Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.

Pellin MA, Wouda RM, Robinson K, Tsimbas K, Kurzman ID, Biller BJ, Vail DM.

Vet Comp Oncol. 2017 Sep;15(3):919-931. doi: 10.1111/vco.12232. Epub 2016 May 5.

PMID:
27146577
4.

Neurokinin-1 receptor expression and antagonism by the NK-1R antagonist maropitant in canine melanoma cell lines and primary tumour tissues.

Borrego JF, Huelsmeyer MK, Pinkerton ME, Muszynski JL, Miller SA, Kurzman ID, Vail DM.

Vet Comp Oncol. 2016 Jun;14(2):210-24. doi: 10.1111/vco.12093. Epub 2014 Apr 22.

PMID:
24751104
5.

Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.

Pan X, Tsimbas K, Kurzman ID, Vail DM.

Vet Comp Oncol. 2016 Jun;14(2):202-9. doi: 10.1111/vco.12091. Epub 2014 Apr 16.

PMID:
24735385
6.

GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.

Thamm DH, Vail DM, Kurzman ID, Babusis D, Ray AS, Sousa-Powers N, Tumas DB.

BMC Vet Res. 2014 Jan 25;10:30. doi: 10.1186/1746-6148-10-30.

7.

Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma.

Kozicki AR, Robat C, Chun R, Kurzman ID.

Vet Comp Oncol. 2015 Sep;13(3):229-36. doi: 10.1111/vco.12040. Epub 2013 May 10.

PMID:
23663234
8.

Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.

Vail DM, Husbands BD, Kamerling SG, Simpson H, Kurzman ID, McDonnell A.

J Vet Intern Med. 2012 May-Jun;26(3):608-13. doi: 10.1111/j.1939-1676.2012.00896.x. Epub 2012 Mar 9.

9.

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.

Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD.

Am J Vet Res. 2011 Dec;72(12):1631-8. doi: 10.2460/ajvr.72.12.1631.

PMID:
22126691
10.

Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation.

Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ 3rd, Kraft SL, Gustafson DL, Vail DM.

Clin Cancer Res. 2010 Mar 1;16(5):1498-508. doi: 10.1158/1078-0432.CCR-09-2804. Epub 2010 Feb 16.

11.

RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.

Thamm DH, Huelsmeyer MK, Mitzey AM, Qurollo B, Rose BJ, Kurzman ID.

Melanoma Res. 2010 Feb;20(1):35-42. doi: 10.1097/CMR.0b013e328331ca86.

PMID:
19949352
12.

Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.

Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB.

Clin Cancer Res. 2009 May 15;15(10):3503-10. doi: 10.1158/1078-0432.CCR-08-3113. Epub 2009 May 5.

13.

Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma.

Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail DM.

Vet Comp Oncol. 2007 Dec;5(4):219-31. doi: 10.1111/j.1476-5829.2007.00128.x.

PMID:
19754780
14.

Clinical signs, treatments, and outcome in cats with transitional cell carcinoma of the urinary bladder: 20 cases (1990-2004).

Wilson HM, Chun R, Larson VS, Kurzman ID, Vail DM.

J Am Vet Med Assoc. 2007 Jul 1;231(1):101-6. Erratum in: J Am Vet Med Assoc. 2007 Nov 15;231(10):1533.

PMID:
17605672
15.

Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?

MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM.

J Vet Intern Med. 2005 Sep-Oct;19(5):732-6.

16.

Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.

Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG.

Clin Cancer Res. 2005 Jul 1;11(13):4827-34.

17.

Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.

Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, Macewen EG, Vail DM.

Cancer Immunol Immunother. 2006 Apr;55(4):433-42. Epub 2005 Jun 18.

PMID:
15965647
18.

Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs.

Marr AK, Kurzman ID, Vail DM.

Am J Vet Res. 2004 Nov;65(11):1474-8.

PMID:
15566083
19.

Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery.

Ma Y, Manolache S, Denes FS, Thamm DH, Kurzman ID, Vail DM.

J Biomater Sci Polym Ed. 2004;15(8):1033-49.

PMID:
15461188
20.

Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.

Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM.

Cancer Chemother Pharmacol. 2004 Jul;54(1):25-33. Epub 2004 Apr 17.

PMID:
15108021
21.

IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.

MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, Wilson M, Radinsky R.

J Cell Biochem. 2004 May 1;92(1):77-91.

PMID:
15095405
22.

The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro.

Poirier VJ, Huelsmeyer MK, Kurzman ID, Thamm DH, Vail DM.

Vet Comp Oncol. 2003 Dec;1(4):207-15. doi: 10.1111/j.1476-5810.2003.00026.x.

PMID:
19379182
23.

In vitro effects of 2-methoxyestradiol on canine tumour cells.

Marr AK, Thamm DH, Kurzman ID, Vail DM, MacEwen EG.

Vet Comp Oncol. 2003 Sep;1(3):159-67. doi: 10.1111/j.1476-5829.2003.00022.x.

PMID:
19379315
24.

Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.

Thamm DH, Kurzman ID, Macewen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT.

Cancer Immunol Immunother. 2003 Aug;52(8):473-80. Epub 2003 May 27.

PMID:
12768328
25.

Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats.

Poirier VJ, Thamm DH, Kurzman ID, Jeglum KA, Chun R, Obradovich JE, O'Brien M, Fred RM 3rd, Phillips BS, Vail DM.

J Vet Intern Med. 2002 Nov-Dec;16(6):726-31.

26.

STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.

Vail DM, Kurzman ID, Glawe PC, O'Brien MG, Chun R, Garrett LD, Obradovich JE, Fred RM 3rd, Khanna C, Colbern GT, Working PK.

Cancer Chemother Pharmacol. 2002 Aug;50(2):131-6. Epub 2002 Jun 14.

PMID:
12172978
27.

Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study.

Chun R, Kurzman ID, Couto CG, Klausner J, Henry C, MacEwen EG.

J Vet Intern Med. 2000 Sep-Oct;14(5):495-8.

28.

Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma.

Fox LE, Rosenthal RC, King RR, Levine PB, Vail DM, Helfand SC, MacEwen EG, Perez-Soler R, Calderwood-Mays M, Kurzman ID.

Am J Vet Res. 2000 Jul;61(7):791-5.

PMID:
10895902
29.

In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.

Kurzman ID, Shi F, Vail DM, MacEwen EG.

Cancer Biother Radiopharm. 1999 Apr;14(2):121-8.

PMID:
10850295
30.

Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors.

Ginn PE, Fox LE, Brower JC, Gaskin A, Kurzman ID, Kubilis PS.

Vet Pathol. 2000 Jan;37(1):33-9.

PMID:
10643978
31.

Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.

MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Everlith K, Madewell BR, Rodriguez CO Jr, Phillips B, Zwahlen CH, Obradovich J, Rosenthal RC, Fox LE, Rosenberg M, Henry C, Fidel J.

Clin Cancer Res. 1999 Dec;5(12):4249-58.

32.

Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model.

Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, Imondi AR, Vail DM.

Clin Cancer Res. 1999 Sep;5(9):2653-9.

33.
34.

Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors.

Wolf JC, Ginn PE, Homer B, Fox LE, Kurzman ID.

Vet Pathol. 1997 Sep;34(5):394-404.

PMID:
9381650
35.

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993).

Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hale A, Kruth SA, Klein MK, Klausner J, Norris AM, McCaw D, Straw RC, Withrow SJ.

J Vet Intern Med. 1996 Mar-Apr;10(2):76-81.

36.

Canine osteosarcoma: amputation and chemoimmunotherapy.

MacEwen EG, Kurzman ID.

Vet Clin North Am Small Anim Pract. 1996 Jan;26(1):123-33. Review.

PMID:
8825571
37.

Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.

Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, et al.

Clin Cancer Res. 1995 Dec;1(12):1595-601.

38.

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.

Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO Jr, et al.

Clin Cancer Res. 1995 Oct;1(10):1165-70.

39.

The effect of high fat diet and dehydroepiandrosterone (DHEA) administration in the rhesus monkey.

Christopher-Hennings J, Kurzman ID, Haffa AL, Kemnitz JW, Macewen EG.

In Vivo. 1995 Sep-Oct;9(5):415-20.

PMID:
8900917
40.
41.

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.

Fox LE, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Vail DM, Kisseberth W, London C, Madewell BR, Rodriguez CO Jr.

Cancer Biother. 1995 Summer;10(2):125-30. Erratum in: Cancer Biother 1995 Fall;10(3):249.

PMID:
7663571
42.

Prognostic factors for treatment of malignant lymphoma in dogs.

Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG.

J Am Vet Med Assoc. 1994 Dec 15;205(12):1722-8.

PMID:
7744644
43.

Hypocholesterolemic effect of exogenous dehydroepiandrosterone administration in the rhesus monkey.

Haffa AL, MacEwen EG, Kurzman ID, Kemnitz JW.

In Vivo. 1994 Nov-Dec;8(6):993-7.

PMID:
7772752
44.
45.

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.

MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox LE, Keller ET, Obradovich J, et al.

J Drug Target. 1994;2(5):391-6.

PMID:
7704483
46.
47.
48.
49.

Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells.

Smith BW, Kurzman ID, Schultz KT, Czuprynski CJ, MacEwen EG.

Cancer Biother. 1993 Summer;8(2):137-44.

PMID:
7804354
50.

Supplemental Content

Loading ...
Support Center